董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Sandipan Bhowmik | -- | Director | -- | 未披露 | 未持股 | 2023-02-16 |
| Denny Cheuk Kai Tse | -- | Director | -- | 未披露 | 未持股 | 2023-02-16 |
| Nigel Valentino Trayers | -- | Director | -- | 未披露 | 未持股 | 2023-02-16 |
高管介绍
注：高管持股数取自最新公司公告
董事简历
中英对照 | 中文 | 英文- Sandipan Bhowmik
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Denny Cheuk Kai Tse
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Nigel Valentino Trayers
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
高管简历
中英对照 | 中文 | 英文- 郑汀
郑汀被任命为公司首席执行官。自2003年起，郑女士一直负责脐带血库的运营，包括CCBC的业务拓展及全方位管理。除此之外，她还负责CCBC的战略业务拓展，收购项目的规划和协商，以及企业整体战略的制定和执行。她在中国医疗行业已累积超过十多年的经验，包括公司财务，内部审计以及公司战略和发展等。郑女士自2001年9月开始曾经担任金卫医疗的执行董事职务，主要负责金卫医疗及其下属子公司的财务和内部审计，并在金卫医疗于2001年12月在香港联合交易所有限公司创业板上市的过程中发挥重要作用。郑女士从2012年8月开始成为金卫医疗的非执行董事。她在公司并购诺亚（广东省脐血库）以及投资于CordLife（Life Corporation Limited 及康盛人生集团有限公司）过程中亦担任非常重要的角色。在加入公司之前，郑女士于1997年至2001年曾就职于华实会计师事务所。郑女士毕业于中国人民大学，获颁授高级管理人员工商管理硕士学位。郑女士现任中国脐带血库企业集团（「CCBC」，公司的一间联营公司及一间于纽约证券交易所上市之公司）之主席兼首席执行官，负责该公司的策略管理。2012年8月23日起获委任金卫医疗集团有限公司非执行董事。
Ting Zheng, serves as Global Cord Blood Corporation chief executive officer since 2009 and chairperson of the Board since 2018 and is the chairperson of the Nominating and Corporate Governance Committee and chairperson of the Litigation Steering Committee. She has been in charge of Global Cord Blood Corporation cord blood bank operations since 2003 and is responsible for the strategic direction, development and overall management of GCBC. Aside from overseeing the overall operation of GCBC, she is also responsible for strategic developments, acquisition planning and negotiations, and formulating overall business strategy and various business initiatives of GCBC. She has more than sixteen years of experience in the fields of accounting, internal control, and corporate strategies and development in China's healthcare industry. Ms. Zheng has served as an executive director of Golden Meditech and has been in charge of its and its subsidiaries' financial and internal control systems since September 2001. She assumed a critical role in the initial public offering by Golden Meditech on the Growth Enterprise Market of the Hong Kong Stock Exchange in December 2001. Between August 2012 and May 2019 Ms. Zheng served as a non-executive director of Golden Meditech. She played an important role in Global Cord Blood Corporation acquisition of Nuoya and investments in Cordlife. Prior to joining Global Cord Blood Corporation, Ms. Zheng worked for Sino-reality Certified Public Accountants, an accounting firm in China, from 1997 to 2001. She received an Executive MBA degree from Renmin University of China. With effect from April 1 2017 Ms. Zheng also serves as the interim chief executive officer of Global Cord Blood Corporation Beijing division.- 郑汀被任命为公司首席执行官。自2003年起，郑女士一直负责脐带血库的运营，包括CCBC的业务拓展及全方位管理。除此之外，她还负责CCBC的战略业务拓展，收购项目的规划和协商，以及企业整体战略的制定和执行。她在中国医疗行业已累积超过十多年的经验，包括公司财务，内部审计以及公司战略和发展等。郑女士自2001年9月开始曾经担任金卫医疗的执行董事职务，主要负责金卫医疗及其下属子公司的财务和内部审计，并在金卫医疗于2001年12月在香港联合交易所有限公司创业板上市的过程中发挥重要作用。郑女士从2012年8月开始成为金卫医疗的非执行董事。她在公司并购诺亚（广东省脐血库）以及投资于CordLife（Life Corporation Limited 及康盛人生集团有限公司）过程中亦担任非常重要的角色。在加入公司之前，郑女士于1997年至2001年曾就职于华实会计师事务所。郑女士毕业于中国人民大学，获颁授高级管理人员工商管理硕士学位。郑女士现任中国脐带血库企业集团（「CCBC」，公司的一间联营公司及一间于纽约证券交易所上市之公司）之主席兼首席执行官，负责该公司的策略管理。2012年8月23日起获委任金卫医疗集团有限公司非执行董事。
- Ting Zheng, serves as Global Cord Blood Corporation chief executive officer since 2009 and chairperson of the Board since 2018 and is the chairperson of the Nominating and Corporate Governance Committee and chairperson of the Litigation Steering Committee. She has been in charge of Global Cord Blood Corporation cord blood bank operations since 2003 and is responsible for the strategic direction, development and overall management of GCBC. Aside from overseeing the overall operation of GCBC, she is also responsible for strategic developments, acquisition planning and negotiations, and formulating overall business strategy and various business initiatives of GCBC. She has more than sixteen years of experience in the fields of accounting, internal control, and corporate strategies and development in China's healthcare industry. Ms. Zheng has served as an executive director of Golden Meditech and has been in charge of its and its subsidiaries' financial and internal control systems since September 2001. She assumed a critical role in the initial public offering by Golden Meditech on the Growth Enterprise Market of the Hong Kong Stock Exchange in December 2001. Between August 2012 and May 2019 Ms. Zheng served as a non-executive director of Golden Meditech. She played an important role in Global Cord Blood Corporation acquisition of Nuoya and investments in Cordlife. Prior to joining Global Cord Blood Corporation, Ms. Zheng worked for Sino-reality Certified Public Accountants, an accounting firm in China, from 1997 to 2001. She received an Executive MBA degree from Renmin University of China. With effect from April 1 2017 Ms. Zheng also serves as the interim chief executive officer of Global Cord Blood Corporation Beijing division.
- 岚山芮
岚山芮现任公司广东及浙江脐血库的首席执行官，负责诺亚及绿蔻的日常经营与管理，以及广东及浙江本地市场战略的制定和执行。她在2009年3月加入诺亚，并拥有超过十年的中国市场营销经验，对于中国的消费市场和政策环境具有深刻的了解。1999年至2009年，她就职于日本加特可自动变速箱有限公司，负责新业务和新市场的拓展，战略执行和成本控制。1989年至1999年，她任职于日产自动车株式会社，负责包括中国，中国香港和新加坡的整体海外市场的销售。岚山女士于 1981年毕业于北京第二外国语学院日语系，并于1988年完成日本上智大学的公共媒体学研究课程。
Rui Arashiyama, serves as Global Cord Blood Corporation chief executive officer in the Guangdong and Zhejiang divisions since 2009. She oversees the daily operations and management of Nuoya and Lukou and is responsible for the formulation and implementation of marketing strategy for the two markets. She joined Nuoya in March 2009 and has over 16 years of sales and marketing experiences in China and in-depth knowledge about China's consumer market and regulatory environment. From 1999 to 2009 she worked for Jatco Company Limited and was responsible for new business and new market development, execution and cost management. Between 1989 and 1999 she was with Nissan Motor Company Limited with main responsibilities of overseas market development including China, Hong Kong and Singapore. She graduated from Beijing International Studies University previously known as Beijing Second Foreign Languages Institute in 1981 with a bachelor's degree of Japanese culture. In 1988 she completed a postgraduate mass media program in Japan Sophia University.- 岚山芮现任公司广东及浙江脐血库的首席执行官，负责诺亚及绿蔻的日常经营与管理，以及广东及浙江本地市场战略的制定和执行。她在2009年3月加入诺亚，并拥有超过十年的中国市场营销经验，对于中国的消费市场和政策环境具有深刻的了解。1999年至2009年，她就职于日本加特可自动变速箱有限公司，负责新业务和新市场的拓展，战略执行和成本控制。1989年至1999年，她任职于日产自动车株式会社，负责包括中国，中国香港和新加坡的整体海外市场的销售。岚山女士于 1981年毕业于北京第二外国语学院日语系，并于1988年完成日本上智大学的公共媒体学研究课程。
- Rui Arashiyama, serves as Global Cord Blood Corporation chief executive officer in the Guangdong and Zhejiang divisions since 2009. She oversees the daily operations and management of Nuoya and Lukou and is responsible for the formulation and implementation of marketing strategy for the two markets. She joined Nuoya in March 2009 and has over 16 years of sales and marketing experiences in China and in-depth knowledge about China's consumer market and regulatory environment. From 1999 to 2009 she worked for Jatco Company Limited and was responsible for new business and new market development, execution and cost management. Between 1989 and 1999 she was with Nissan Motor Company Limited with main responsibilities of overseas market development including China, Hong Kong and Singapore. She graduated from Beijing International Studies University previously known as Beijing Second Foreign Languages Institute in 1981 with a bachelor's degree of Japanese culture. In 1988 she completed a postgraduate mass media program in Japan Sophia University.
- 陈炳泉
陈炳泉现任首席财政官兼公司董事，负责CCBC财务相关事宜，包括会计和预算计划。他还负责CCBC的业务拓展，包括企业并购以及对海外医疗公司的投资等，在公司诺亚（广东省脐血库）以及投资于CordLife（Life Corporation Limited 及康盛人生集团有限公司）过程中发挥重要作用。陈先生自2005年3月加入金卫医疗，并担任企业融资副总裁；在加入公司前，陈先生曾先后就职于多家在港的国际金融机构，包括SalomonSmithBarney，DBS Vickers Securities以及 UOB Kay Hian。他在2003年至2005年3月于UOB Kay Hian担任高级分析师期间专门从事医药行业证券分析工作，并于2003年被 Asia Money 杂志评选为亚洲最佳小市值公司分析师。陈先生拥有特许财务分析师（CFA）资格。他于1999年毕业于加拿大Queen's University商学院，获金融和会计学士学位。
Albert Chen, serves as Global Cord Blood Corporation chief financial officer and a director since 2009. He is in charge of GCBC's finance-related matters, including accounting and budget planning. He is also involved in GCBC's corporate structuring and development, including mergers and acquisitions, and investment in foreign healthcare companies. For example, he played an important role in Global Cord Blood Corporation acquisition of Nuoya and investments in Cordlife. He had served as the corporate finance vice president of Golden Meditech since March 2005. Prior to joining Golden Meditech, Mr. Chen worked in a number of financial institutions, including SalomonSmithBarney, DBS Vickers Securities and UOB Kay Hian in Hong Kong. Mr. Chen is a CFA charterholder. He received his bachelor's degree in commerce from Queen's University, Canada, School of Business in 1999 with a major in finance and accounting.- 陈炳泉现任首席财政官兼公司董事，负责CCBC财务相关事宜，包括会计和预算计划。他还负责CCBC的业务拓展，包括企业并购以及对海外医疗公司的投资等，在公司诺亚（广东省脐血库）以及投资于CordLife（Life Corporation Limited 及康盛人生集团有限公司）过程中发挥重要作用。陈先生自2005年3月加入金卫医疗，并担任企业融资副总裁；在加入公司前，陈先生曾先后就职于多家在港的国际金融机构，包括SalomonSmithBarney，DBS Vickers Securities以及 UOB Kay Hian。他在2003年至2005年3月于UOB Kay Hian担任高级分析师期间专门从事医药行业证券分析工作，并于2003年被 Asia Money 杂志评选为亚洲最佳小市值公司分析师。陈先生拥有特许财务分析师（CFA）资格。他于1999年毕业于加拿大Queen's University商学院，获金融和会计学士学位。
- Albert Chen, serves as Global Cord Blood Corporation chief financial officer and a director since 2009. He is in charge of GCBC's finance-related matters, including accounting and budget planning. He is also involved in GCBC's corporate structuring and development, including mergers and acquisitions, and investment in foreign healthcare companies. For example, he played an important role in Global Cord Blood Corporation acquisition of Nuoya and investments in Cordlife. He had served as the corporate finance vice president of Golden Meditech since March 2005. Prior to joining Golden Meditech, Mr. Chen worked in a number of financial institutions, including SalomonSmithBarney, DBS Vickers Securities and UOB Kay Hian in Hong Kong. Mr. Chen is a CFA charterholder. He received his bachelor's degree in commerce from Queen's University, Canada, School of Business in 1999 with a major in finance and accounting.
- 徐欣
徐欣现任公司首席技术官，负责脐带血库实验室的日常管理以及实验室流程控制，确保脐带血造血干细胞在处理、分离和制备过程中严格遵守国家标准。徐女士在细胞生物学领域拥有超过20年经验。在2004年11月加入公司之前，她曾任教于北京医科大学细胞生物学专业。
Xin Xu, serves as Global Cord Blood Corporation chief technology officer since 2004. She is in charge of the daily operations and logistic control of the cord blood bank laboratories, and oversees the laboratories procedures in relation to the processing, separation and preservation of cord blood stem cells to ensure the laboratories environment strictly complies with national standards. Prior to joining Gravitas Education Holdings, Inc. in November 2004 Ms. Xu had over 25 years of solid experience in cryobiology research and had lectured in cryobiology at Beijing Medical University.- 徐欣现任公司首席技术官，负责脐带血库实验室的日常管理以及实验室流程控制，确保脐带血造血干细胞在处理、分离和制备过程中严格遵守国家标准。徐女士在细胞生物学领域拥有超过20年经验。在2004年11月加入公司之前，她曾任教于北京医科大学细胞生物学专业。
- Xin Xu, serves as Global Cord Blood Corporation chief technology officer since 2004. She is in charge of the daily operations and logistic control of the cord blood bank laboratories, and oversees the laboratories procedures in relation to the processing, separation and preservation of cord blood stem cells to ensure the laboratories environment strictly complies with national standards. Prior to joining Gravitas Education Holdings, Inc. in November 2004 Ms. Xu had over 25 years of solid experience in cryobiology research and had lectured in cryobiology at Beijing Medical University.